Optimal global value of information trials: Better aligning manufacturer and decision maker interests and enabling feasible risk sharing

PharmacoEconomics

Volumn 31, Issue 5, 2013, Pages 393-401

  Eckermann, Simon ^a   Willan, Andrew R ^b,c  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATTRIBUTABLE RISK; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COMPENSATION; COST; DECISION MAKING; DEFENSE MECHANISM; FOLLOW UP; FUNDING; HUMAN; INSURANCE; INVESTMENT; MEDICAL INFORMATION; MEDICAL TECHNOLOGY; PRIORITY JOURNAL; PUBLIC HEALTH; REIMBURSEMENT; REVIEW; RISK FACTOR; STUDY DESIGN; THERAPY; UNCERTAINTY;

BIOMEDICAL TECHNOLOGY; COOPERATIVE BEHAVIOR; DECISION MAKING; DIFFUSION OF INNOVATION; DRUG INDUSTRY; HUMANS; INFORMED CONSENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RESEARCH SUBJECTS; RISK SHARING, FINANCIAL; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84877966637     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0038-5     Document Type: Review

References (23)

1. Tunis SR, Pearson SD. Coverage options for promising technologies: Medicare's 'coverage with evidence development'. Health Aff (Millwood). 2006;25:1218-30.
2. Hutton J, Trueman P, Henshall C. Coverage with evidence development: an examination of conceptual and policy issues. Int J Health Technol Assess Health Care. 2007;23(4):425-35.
3. Cook J, Vernon J, Manning R. Pharmaceutical risk-sharing agreements. Pharmacoeconomics. 2008;26(7):551-6.
4. Towse A, Garrison L. Can't get no satisfaction? Will pay for performance help? Toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products. Pharmacoeconomics. 2010;28(2):93-102.
5. Graham D. Public expenditure under uncertainty: the net benefit criteria. Am Econ Rev. 1992;82(4):822-46.
6. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Mak. 1998;18(Suppl):S68-80.
7. Eckermann S, Willan A. Presenting evidence and summary measures to best inform societal decisions when comparing multiple strategies. Pharmacoeconomics. 2011;29(7):563-77.
8. Eckermann S, Willan AR. Expected value of information and decision making in HTA. Health Econ. 2007;16:195-209.
9. Eckermann S, Willan AR. Time and EVSI wait for no patient. Value Health. 2008;11:522-6.
10. Eckermann S, Willan AR. The option value of delay in health technology assessment. Med Decis Mak. 2008;28:300-5.
11. Eckermann S, Willan AR. Globally optimal trial design for local decision making. Health Econ. 2009;18:203-16.
12. Willan AR, Eckermann S. Optimal clinical trial design using value of information methods with imperfect implementation. Health Econ. 2010;19:549-61.
13. Willan AR. Optimal sample size determinations from an industry perspective based on the expected value of information. Clin Trials. 2008;5:587-94.
14. Willan AR, Eckermann S. Expected value of information and pricing new health care interventions. Pharmacoeconomics. 2012;30(6):447-59.
15. Eckermann S, Karnon J, Willan A. The value of value of information: best informing research design and prioritization using current methods. Pharmacoeconomics. 2010;28(9):699-709.
16. Eckermann S, Coory M, Willan AR. Consistently estimating absolute risk difference when translating evidence to jurisdictions of interest. Pharmacoeconomics. 2011;29(2):87-96.
17. Eckermann S, Coory M, Willan AR. Indirect comparison: relative risk fallacies and odds solution. J Clin Epidemiol. 2009;62:1031-6.
18. Chung TY. Incomplete contracts, specific investments, and risk sharing. Rev Econ Stud. 1991;58(5):1031-42.
19. Maskin E, Tirole J. Unforeseen contingencies and incomplete contracts. Rev Econ Stud. 1999;66(1, Special Issue: Contracts):83-114.
20. Angell M. The truth about the drug companies. New York: Random House; 2004.
21. Baker B, Johnsrud T, Crimsom M, Rosenheck R, Woods S. Quantitative analysis of sponsorship bias in economic studies of antidepressants. Brit J Psychiatry. 2003;183:498-506. doi: 10.1192/03-2.
22. Angell M. Is academic medicine for sale? N Engl J Med. 2000;342(20):1516-8.
23. O'Brien B. Frankenstein's monster or vampire of trials? (Supplement: Standards for Economic Evaluation of Drugs: Issues and Answers). Med Care. 1996;34(12):DS99-DS108.